<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111108">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113865</url>
  </required_header>
  <id_info>
    <org_study_id>FMM115392013</org_study_id>
    <nct_id>NCT02113865</nct_id>
  </id_info>
  <brief_title>Score System for Prediction Risk and Early Diagnosis of HCC in HIV/HCV Patients</brief_title>
  <official_title>Obtención de un Panel de puntuación (&quot;Score System&quot;) Para la predicción de Riesgo Individualizado y la detección Precoz de Carcinoma Hepatocelular (HCC) en Sujetos Coinfectados VIH/VHC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish a clinical score panel based on clinical, molecular
      and genetic parameters that allow us to stratify and obtain an early detection of patients
      with an increased risk of developing hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transversal study design like a &quot;proof of concept&quot;.

      Primary objective:

      The main objective is try to stablish a descriptive panel (first phase of a score system)
      based in the conjunction or sum of several clinical and laboratory parameters (molecular and
      genetic factors). The aim is to detect in a fast, early and successful way those patients
      that presents a high risk to develop an hepatocellular carcinoma (HCC) in the future in a
      specific population: HIV and HCV coinfected patients. The establishment of this panel will
      allow clinicians set up a correct treatment decreasing the probability of liver cirrhosis
      and HCC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Sera inflammatory markers</measure>
    <time_frame>1 day (Routine visit to normal following in Infectious Disease Department)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inflammatory markers will be measure used a Enzyme-linked Immunosorbent Assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sera apoptotic markers</measure>
    <time_frame>1 day (Routine visit in disease following at Infectious Disease Department)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apoptotic markers will be evaluated through a Enzyme-linked Immunosorbent Assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of genetic polymorphisms distribution between study groups of relevant genes probably implicated in the disease</measure>
    <time_frame>1 day (Routine visit in normal following at Infectious Disease Department)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genetic polymorphisms will be evaluated using Real-Time polymerase chain reaction technique</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acquired Immunodeficiency Syndrome Virus</condition>
  <condition>Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Grupo 0</arm_group_label>
    <description>Null or mild fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grupo 1</arm_group_label>
    <description>Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grupo 2</arm_group_label>
    <description>HCC diagnosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, white cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV/HCV coinfected patients from Infectious Diseases Department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human immunodeficiency virus chronic infection

          -  Hepatitis C virus chronic infection

          -  No other liver viral coinfections

        Exclusion Criteria:

          -  Alcohol consume

          -  Immunosuppressor or immunoactive treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz S Sastre, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para la Investigación Biomédica del Hospital Ramón y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Itziar de Pablo</last_name>
      <email>itziar.pablo@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Sastre</last_name>
      <email>bsastre@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Beatriz Sastre, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
